SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex ($CETX) is trending due to a massive premarket surge and multiple trading halts, sparking high volatility. Community chatter revolves around a potential short squeeze reminiscent of $SMX and predictions of continued upward momentum, with some suggesting extremely high price targets. The stock's nano float and recent acquisition news are also fueling the discussion.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

Treasure Global is trending due to a recent revenue target update and chatter around its low float, sparking comparisons to other high-flying stocks like $SMX. Community members are actively discussing the potential for a significant short squeeze, citing high borrow rates and limited share availability. Some investors believe the stock could reach new highs, while others caution about the risks associated with low-float stocks and potential dilution.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors debate the impact of competitor GPCR's data, particularly focusing on the lack of safety data released and potential implications for Viking's market position. Community discussions revolve around potential partnerships or a buyout, with some emphasizing Viking's strong pipeline and advanced stage in development. There is also ongoing speculation about the possibility of VK2809 skipping Phase 3 trials based on new FDA guidance.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences ($WVE) is trending following positive Phase 1 data for its obesity drug, WVE-007, which showed fat loss without muscle loss. The community is excited about the potential for infrequent dosing and is speculating about a possible offering or buyout. Discussions revolve around the significance of the data, potential price targets, and whether this is a Reddit-driven short squeeze.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to its impending inclusion in the S&P 500, driving significant after-hours price movement. While some investors celebrate the milestone and anticipate further gains, others express concerns about the company's fundamentals and accounting practices, suggesting a potential "sell the news" event. Community discussions revolve around whether the stock is overvalued and if a substantial correction is on the horizon.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as traders discuss its potential for a low-float squeeze, drawing comparisons to recent runners in the same sector like $SMX. The community is analyzing the stock's float and short borrow fee, with some expressing caution due to a recent offering and warrant dilution. Overall, the focus remains on whether it can achieve a similar explosive move based on its low float.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery ($WBD) is trending amid a potential takeover, with Paramount ($PARA) launching a hostile bid, challenging Netflix's ($NFLX) deal and igniting a bidding war. Community discussion revolves around the merits of each offer, regulatory hurdles, and potential outcomes for shareholders. The stock has seen significant gains YTD, fueled by M&A rumors and speculation.

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

PMGC Holdings Inc

PMGC Holdings Inc.

ELAB is trending due to a premarket surge, fueled by retail trader interest in PMGC Holdings' shift towards biotech and industrial sectors. Community discussions revolve around the stock's low float and potential for a squeeze, while some traders are pointing to possible overextension. The stock's volatility and previous reverse splits are also being discussed.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending following Phase 2 data highlighting weight loss percentages, though some investors are wary due to the omission of certain safety data in the initial report. The community is actively discussing the tolerability of the drug, particularly regarding liver enzyme elevations and adverse events like vomiting, while also speculating about potential short squeezes and comparisons to competitors like $LLY and $VKTX. Some see it as a potential acquisition target in the competitive GLP-1 space.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss the potential for a buyout or strategic partnership, fueled by promising data in lung, prostate, and pancreatic cancers. Community talking points center on the company being significantly undervalued with a large short interest, positioning it for a potential squeeze. Some are pointing to a recent analyst upgrade and upcoming presentation as potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company stated that results from&nbsp;aleniglipron achieved a mean weight loss of 11.3%&nbsp;at 36 weeks&nbsp;in the&nbsp;Phase 2b ACCESS study.</li><li>In the ACCESS II study, the mean weight loss clocked was up to 15.3%.</li><li>Based on these results, aleniglipron will proceed into Phase 3 clinical development, the firm noted.&nbsp;</li></ul>Shares of Structure Therapeutics (GPCR) shot up over 30% pre-market on Monday after the company&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">announced positive&nbsp;topline data</a> from an ACCESS clinical program of aleniglipron, a weight loss pill.&nbsp;“The topline results presented today show that aleniglipron is differentiated and delivered clinically meaningful, competitive and dose-dependent weight loss with a safety profile appropriate for chronic use in a disease that impacts millions of people,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">said</a> Raymond Stevens, CEO of Structure Therapeutics.&nbsp;<h2 class="st-heading-2">Positive Results</h2>The firm’s drug achieved a mean weight loss of 11.3%&nbsp;at 36 weeks&nbsp;in the&nbsp;Phase 2b ACCESS study and up to 15.3% in the ACCESS II study. Following this, aleniglipron will proceed into Phase 3 clinical development, the company said.&nbsp;“The weight-lowering data from these ACCESS studies, without any evidence of a plateau by Week 36, are very encouraging—particularly weight loss of up to 15.3% in ACCESS II that hopefully will be confirmed in larger, longer-term studies,” Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee, said in the note.&nbsp;Noting that obesity is a complex, chronic disease, the drug’s commercial availability could have a profound impact on patients globally, some stakeholders said.&nbsp;The news comes amid the rising popularity of obesity treatment drugs in the U.S., as smaller firms compete for market share with large global drugmakers such as Novo Nordisk and Eli Lilly. According to fresh&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/27/3195649/0/en/Anti-Obesity-Drugs-Market-Size-to-Reach-35-52-Billion-by-2032-Driven-by-Advancements-in-Weight-Management-Therapies-and-Rising-Obesity-Prevalence-SNS-Insider.html">data from SNS Insider</a>, the anti-obesity drugs market size is expected to grow at a compound annual growth rate (CAGR) of 25.59% to reach $35.52 billion by 2032.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GPCR jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1293/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_08_at_7_35_59_PM_png_c05be465cf.webp" alt="On Stocktwits, retail sentiment around GPCR jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels." width="1293" height="156"></figure>One user expects GPCR’s share price to cross $50 on Monday and surge to over $100 by March 2026.&nbsp;<stembedurl>https://stocktwits.com/View2021/message/638471909</stembedurl>Shares of GPCR are up over 68% in the last six months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

Why Did Structure Therapeutics Stock Surge Pre-Market Today?

Shares of Structure Therapeutics shot up over 30% in premarket trading after the company announced positive topline data for its new weight loss pill. 

Equity

Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Capital Fund Management S.A.

Capital Fund Management S.A. cut its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 82.0% in the 2nd quarter, according to its most recent disclosure...

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 6.9% - Here's Why

Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.9% - Here's Why...

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5% - Here's Why

Structure Therapeutics (NASDAQ:GPCR) Shares Down 5.5% - Here's Why...

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven brokerages that are currently covering the stock, Marketbeat...

Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Foresite Capital Management VI LLC

Foresite Capital Management VI LLC decreased its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 50.0% in the 2nd quarter, according to its most recent...

Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6% - Here's What Happened

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 6.6% - What's Next...

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.7% - Here's What Happened

Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.7% - Time to Sell...

Leerink Partnrs Has Pessimistic View of GPCR FY2025 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Stock analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Structure Therapeutics in a...

Structure Therapeutics Inc. Sponsored ADR $GPCR Holdings Boosted by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC raised its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 90.9% in the second quarter, according to the company in its most recent...

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR